304 related articles for article (PubMed ID: 18234990)
1. Subconjunctival topotecan in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Tsui JY; Dalgard C; Van Quill KR; Lee L; Grossniklaus HE; Edelhauser HF; O'Brien JM
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):490-6. PubMed ID: 18234990
[TBL] [Abstract][Full Text] [Related]
2. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Van Quill KR; Dioguardi PK; Tong CT; Gilbert JA; Aaberg TM; Grossniklaus HE; Edelhauser HF; O'Brien JM
Ophthalmology; 2005 Jun; 112(6):1151-8. PubMed ID: 15885791
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel in the treatment of retinal tumors of LH beta-Tag murine transgenic model of retinoblastoma.
Suárez F; Jockovich ME; Hernandez E; Feuer W; Parel JM; Murray TG
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3437-40. PubMed ID: 17652710
[TBL] [Abstract][Full Text] [Related]
4. Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma.
Escalona-Benz E; Jockovich ME; Murray TG; Hayden B; Hernandez E; Feuer W; Windle JJ
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):8-11. PubMed ID: 15623747
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice.
Dawson DG; Gleiser J; Zimbric ML; Darjatmoko SR; Lindstrom MJ; Strugnell SA; Albert DM
Ophthalmology; 2003 Apr; 110(4):835-9. PubMed ID: 12689912
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
Dalgard CL; Van Quill KR; O'Brien JM
Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
[TBL] [Abstract][Full Text] [Related]
7. Iontophoretic delivery of carboplatin in a murine model of retinoblastoma.
Hayden B; Jockovich ME; Murray TG; Kralinger MT; Voigt M; Hernandez E; Feuer W; Parel JM
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):3717-21. PubMed ID: 16936078
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of periocular topotecan in children with intraocular retinoblastoma.
Chantada GL; Fandino AC; Carcaboso AM; Lagomarsino E; de Davila MT; Guitter MR; Rose AB; Manzitti J; Bramuglia GF; Abramson DH
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1492-6. PubMed ID: 18978345
[TBL] [Abstract][Full Text] [Related]
9. Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
Laurie NA; Gray JK; Zhang J; Leggas M; Relling M; Egorin M; Stewart C; Dyer MA
Clin Cancer Res; 2005 Oct; 11(20):7569-78. PubMed ID: 16243833
[TBL] [Abstract][Full Text] [Related]
10. Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro.
Dalezis P; Geromichalos GD; Voyatzi S; Trafalis D; Athanassiou AE; Koutsilieris M; Papageorgiou A
J BUON; 2006; 11(3):323-7. PubMed ID: 17309157
[TBL] [Abstract][Full Text] [Related]
11. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
[TBL] [Abstract][Full Text] [Related]
12. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma.
Kang SJ; Durairaj C; Kompella UB; O'Brien JM; Grossniklaus HE
Arch Ophthalmol; 2009 Aug; 127(8):1043-7. PubMed ID: 19667343
[TBL] [Abstract][Full Text] [Related]
13. External beam radiation "salvage" therapy in transgenic murine retinoblastoma.
Sobrin L; Hayden BC; Murray TG; Cicciarelli N; Scott IU; Hernandez E; Wu X; Markoe AM; Feuer W; Fulton L; O'Brien JM
Arch Ophthalmol; 2004 Feb; 122(2):251-7. PubMed ID: 14769602
[TBL] [Abstract][Full Text] [Related]
14. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
Ji YB; Zhou JH; Zuo MX; You QD
Yao Xue Xue Bao; 2008 Aug; 43(8):811-8. PubMed ID: 18956773
[TBL] [Abstract][Full Text] [Related]
15. Subconjunctival carboplatin in retinoblastoma: impact of tumor burden and dose schedule.
Hayden BH; Murray TG; Scott IU; Cicciarelli N; Hernandez E; Feuer W; Fulton L; O'Brien JM
Arch Ophthalmol; 2000 Nov; 118(11):1549-54. PubMed ID: 11074812
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma.
Abramson DH; Frank CM; Dunkel IJ
Ophthalmology; 1999 Oct; 106(10):1947-50. PubMed ID: 10519590
[TBL] [Abstract][Full Text] [Related]
17. Local carboplatin therapy in transgenic murine retinoblastoma.
Harbour JW; Murray TG; Hamasaki D; Cicciarelli N; Hernández E; Smith B; Windle J; O'Brien JM
Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1892-8. PubMed ID: 8759359
[TBL] [Abstract][Full Text] [Related]
18. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice.
Jockovich ME; Murray TG; Escalona-Benz E; Hernandez E; Feuer W
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1264-8. PubMed ID: 16565356
[TBL] [Abstract][Full Text] [Related]
19. Periocular topotecan for intraocular retinoblastoma.
Mallipatna AC; Dimaras H; Chan HS; Héon E; Gallie BL
Arch Ophthalmol; 2011 Jun; 129(6):738-45. PubMed ID: 21670340
[TBL] [Abstract][Full Text] [Related]
20. The experiment research of subconjunctival injections with etoposide for the treatment of retinoblastoma mice.
Mao Y; Zhongyao W; Huasheng Y; Zheng J; He J; Li W
Yan Ke Xue Bao; 2005 Sep; 21(3):169-74. PubMed ID: 17162856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
